Eric X. Chen
Department of Medical Oncology and Hematology
Princess Margaret Hospital
Rm 5-719
610 University Ave
Canada
Name/email consistency: high
- Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer. Gan, H.K., You, B., Pond, G.R., Chen, E.X. J. Natl. Cancer Inst. (2012)
- Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review. You, B., Gan, H.K., Pond, G., Chen, E.X. J. Clin. Oncol. (2012)
- Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. Chen, E., Jonker, D., Gauthier, I., MacLean, M., Wells, J., Powers, J., Seymour, L. Clin. Cancer Res. (2009)
- Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies. Chen, X., Bies, R.R., Ramanathan, R.K., Zuhowski, E.G., Trump, D.L., Egorin, M.J. Cancer Chemother. Pharmacol. (2005)
- Development of molecular targeted anticancer agents: successes, failures and future directions. Chen, E.X., Siu, L.L. Curr. Pharm. Des. (2005)
- Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. Chen, E.X., Batist, G., Siu, L.L., Bangash, N., Maclean, M., McIntosh, L., Miller, W.H., Oza, A.M., Lathia, C., Petrenciuc, O., Seymour, L. Invest. New. Drugs (2005)
- Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours. Chen, X., Oza, A.M., Kusenda, Z., Yi, Q.L., Kochman, D., Moore, M.J., Davis, A.J., Siu, L.L. Br. J. Cancer (2003)
